Global Cardiovascular Drugs Market to Exceed $111.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Cardiovascular Drugs markets. The world market for cardiovascular Drugs is projected to exceed $111.8 billion by the year 2015. The market is driven by an aging population, significantly large number of patients, and growing incidence of cardiovascular diseases the world over. While the market is dominated by industrialized countries including the US and West European regions, sales growth is led by the emerging economies of Asia-Pacific and Latin America.

Cardiovascular Drugs: A Global Strategic Business Report

Cardiovascular disease continues to be the leading cause of mortality worldwide, despite the declining rates of death since at least two decades. The disease is more prevalent in the developed part of the world than developing, though its incidence is growing in emerging economies. Leading risk factors for cardiovascular diseases include tobacco smoking, high LDL cholesterol, low HDL cholesterol, hypertension, diabetes mellitus, obesity, and a sedentary lifestyle.

The United States dominates the world cardiovascular drugs market as stated by the new market research report on cardiovascular drugs market. The US cardiovascular drugs market, though benefiting from an aging population and a significantly large patient pool, is facing growth constraints with the introduction of prescription drug benefit under the Medicare Part D, increasing need for cost containment, and growing genericization and therapeutic substitution. Among the cardiovascular drug categories, sales are led by antihyperlipidemics (also known as lipid regulators), while prescriptions for ACE inhibitors, angiotensin II antagonists, diuretics, beta-blockers, and calcium channel blockers continue to remain strong.

Key players profiled in the report include Abbott Laboratories Inc., AstraZeneca Plc, Bayer AG, Biovail Corp., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Forest Laboratories Inc., GlaxoSmithKline PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi-aventis, Solvay Pharmaceuticals SA, Takeda Pharmaceutical Company Limited, The Medicines Company, among others.

The report titled "Cardiovascular Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of cardiovascular drug categories, growth drivers, growth inhibitors, research & development, product introductions/, product approvals and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. The study further analyzes the United States and Europe markets by the following drug class - Antihyperlipidemics, Angiotensin II Receptor Blockers, Anti-Thrombotics, ACE Inhibitors, Calcium Channel Blockers, Beta Blockers, Anti-Arrhythmics and Others.

For more details about this comprehensive market research report, please visit -
http://www.strategyr.com/Cardiovascular_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website